Li J, Wang Y, Dong C, Luo L
Int J Oncol. 2024; 65(6).
PMID: 39364739
PMC: 11542963.
DOI: 10.3892/ijo.2024.5700.
Barneh F, Koedijk J, Wijnen N, Meulendijks T, Ashtiani M, Dunnebach E
Haematologica. 2024; 109(12):4131-4136.
PMID: 39113654
PMC: 11609786.
DOI: 10.3324/haematol.2024.285707.
Damiani D, Tiribelli M
Biomedicines. 2024; 12(6).
PMID: 38927401
PMC: 11200794.
DOI: 10.3390/biomedicines12061194.
Liberatore C, Di Ianni M
Int J Mol Sci. 2023; 24(19).
PMID: 37834466
PMC: 10573608.
DOI: 10.3390/ijms241915019.
Zarychta J, Kowalczyk A, Krawczyk M, Lejman M, Zawitkowska J
Cancers (Basel). 2023; 15(11).
PMID: 37296906
PMC: 10252035.
DOI: 10.3390/cancers15112944.
Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives.
Leotta S, Condorelli A, Sciortino R, Milone G, Bellofiore C, Garibaldi B
J Clin Med. 2022; 11(1).
PMID: 35011994
PMC: 8745746.
DOI: 10.3390/jcm11010253.
Treatment of AML Relapse After Allo-HCT.
Webster J, Luznik L, Gojo I
Front Oncol. 2022; 11:812207.
PMID: 34976845
PMC: 8716583.
DOI: 10.3389/fonc.2021.812207.
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia.
Maucher M, Srour M, Danhof S, Einsele H, Hudecek M, Yakoub-Agha I
Cancers (Basel). 2021; 13(24).
PMID: 34944782
PMC: 8699597.
DOI: 10.3390/cancers13246157.
Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia and .
Rennert P, Dufort F, Su L, Sanford T, Birt A, Wu L
Mol Cancer Ther. 2021; 20(10):2071-2081.
PMID: 34253594
PMC: 9398100.
DOI: 10.1158/1535-7163.MCT-20-1030.
Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success.
Michelozzi I, Kirtsios E, Giustacchini A
Cancers (Basel). 2021; 13(11).
PMID: 34198742
PMC: 8201025.
DOI: 10.3390/cancers13112816.
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.
Fiorenza S, Turtle C
BioDrugs. 2021; 35(3):281-302.
PMID: 33826079
DOI: 10.1007/s40259-021-00477-8.
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
Adnan Awad S, Dufva O, Ianevski A, Ghimire B, Koski J, Maliniemi P
Leukemia. 2020; 35(4):1087-1099.
PMID: 32782381
PMC: 8024199.
DOI: 10.1038/s41375-020-01011-5.
